Ectopic expression of cancer-testis antigens in cutaneous T-cell lymphoma patients

Clinical Cancer Research

Volumn 20, Issue 14, 2014, Pages 3799-3808

  Litvinov, Ivan V ^a   Cordeiro, Brendan ^a   Huang, Yuanshen ^c   Zargham, Hanieh ^a   Pehr, Kevin ^a   Doré, Marc André ^b   Gilbert, Martin ^b   Zhou, Youwen ^c   Kupper, Thomas S ^d   Sasseville, Denis ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; CUTANEOUS T CELL LYMPHOMA ASSOCIATED ANTIGEN 1; MESSENGER RNA; PROTEIN P53; ROMIDEPSIN; SPO11 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR JUNB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VORINOSTAT; CTAGE1 PROTEIN, HUMAN; GAMETOCYTE SPECIFIC FACTOR 1, HUMAN; HISTONE DEACETYLASE INHIBITOR; MEMBRANE PROTEIN; NUCLEAR PROTEIN; PROTEIN; SYCP1 PROTEIN, HUMAN; T LYMPHOCYTE ANTIGEN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; CANCER TESTIS GENE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE TARGETING; GTSF1 GENE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REC8 GENE; SPO11 GENE; SYCP1 GENE; SYCP3 GENE; UPREGULATION; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; SKIN TUMOR; TUMOR CELL LINE;

ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MEMBRANE GLYCOPROTEINS; MUTATION; NUCLEAR PROTEINS; PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84904396529     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0307     Document Type: Article

References (55)

1. Alsaleh QA, Nanda A, Al-Ajmi H, Al-Sabah H, Elkashlan M, Al-Shemmari S, et al. Clinicoepidemiological features of mycosis fungoides in Kuwait, 1991-2006. Int J Dermatol 2010;49:1393-8.
2. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009;113:5064-73.
3. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007;143:854-9. (Pubitemid 47076482)
4. Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk 2012;12:291-6.
5. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-85. (Pubitemid 40656118)
6. Sun G, Berthelot C, Li Y, Glass DA II, George D, Pandya A, et al. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol 2009;60:231-5.
7. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24:175-208.
8. Muraoka D, Kato T, Wang L, Maeda Y, Noguchi T, Harada N, et al. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. J Immunol 2010;185:3768-76.
9. Nishikawa H, Maeda Y, Ishida T, Gnjatic S, Sato E, Mori F, et al. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. Blood 2012;119:3097-104.
10. Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008;181:776-84.
11. Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A 2006;103:14453-8. (Pubitemid 44484771)
12. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009;100:2014-21.
13. Mathieu MG, Miles AK, Li G, McArdle SE, Rees RC. Cancer/testis antigens for therapeutic use. J BUON 2009;14 Suppl 1:S97-102.
14. Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 2009;37:D816-9.
15. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1.
16. Eichmuller S. Towards defining specific antigens for cutaneous lymphomas. Onkologie 2002;25:448-54. (Pubitemid 36160185)
17. Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D. Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A 2001;98:629-34. (Pubitemid 32105094)
18. Eichmuller S, Usener D, Thiel D, Schadendorf D. Tumor-specific antigens in cutaneous T-cell lymphoma: expression and sero-reactivity. Int J Cancer 2003;104:482-7. (Pubitemid 36323920)
19. Haffner AC, Tassis A, Zepter K, Storz M, Tureci O, Burg G, et al. Expression of cancer/testis antigens in cutaneous T cell lymphomas. Int J Cancer 2002;97:668-70. (Pubitemid 34087808)
20. Shin J, Monti S, Aires DJ, Duvic M, Golub T, Jones DA, et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 2007;110:3015-27. (Pubitemid 350006956)
21. Krejsgaard T, Litvinov IV, Wang Y, Xia L, Willerslev-Olsen A, Koralov SB, et al. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood 2013;122:943-50.
22. Litvinov IV, Jones DA, Sasseville D, Kupper TS. Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. Clin Cancer Res 2010;16:2106-14.
23. Litvinov IV, Kupper TS, Sasseville D. The role of AHI1 and CDKN1C in cutaneous T-cell lymphoma progression. Exp Dermatol 2012;21:964-6.
24. Litvinov IV, Zhou Y, Kupper TS, Sasseville D. Loss of BCL7A expression correlates with poor disease prognosis in patients with earlystage cutaneous T-cell lymphoma. Leuk Lymphoma 2013;54:653-4.
25. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classi fication of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-22. (Pubitemid 47443880)
26. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234-40. (Pubitemid 34517663)
27. Bunn PA Jr, Foss FM. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). J Cell Biochem Suppl 1996;24:12-23.
28. Chen TR. Karyotypic derivation of H9 cell line expressing human immunodeficiency virus susceptibility. J Natl Cancer Inst 1992;84:1922-6.
29. Abrams JT, Lessin S, Ghosh SK, Ju W, Vonderheid EC, Nowell P, et al. A clonal CD4-positive T-cell line established from the blood of a patient with Sezary syndrome. J Invest Dermatol 1991;96:31-7.
30. Kaltoft K, Bisballe S, Dyrberg T, Boel E, Rasmussen PB, Thestrup-Pedersen K. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol 1992;28A:161-7.
31. Kaltoft K, Bisballe S, Rasmussen HF, Thestrup-Pedersen K, Thomsen K, Sterry W. A continuous T-cell line from a patient with Sezary syndrome. Arch Dermatol Res 1987;279:293-8. (Pubitemid 17092161)
32. Starkebaum G, Loughran TP Jr, Waters CA, Ruscetti FW. Establishment of an IL-2 independent, human T-cell line possessing only the p70 IL-2 receptor. Int J Cancer 1991;49:246-53.
33. Wasik MA, Seldin DC, Butmarc JR, Gertz R, Marti R, Maslinski W, et al. Analysis of IL-2, IL-4 and their receptors in clonally-related cell lines derived from a patient with a progressive cutaneous T-cell lymphoproliferative disorder. Leuk Lymphoma 1996;23:125-36. (Pubitemid 26359951)
34. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, Isaacs JT. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res 2006;66:8598-607. (Pubitemid 44449174)
35. Shlien A, Tabori U, Marshall CR, Pienkowska M, Feuk L, Novokmet A, et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A 2008;105:11264-9.
36. Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 2010;28:1345-50.
37. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365-86.
38. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
39. Usener D, Schadendorf D, Koch J, Dubel S, Eichmuller S. cTAGE: a cutaneous T cell lymphoma associated antigen family with tumorspecific splicing. J Invest Dermatol 2003;121:198-206. (Pubitemid 36900473)
40. Kalejs M, Ivanov A, Plakhins G, Cragg MS, Emzinsh D, Illidge TM, et al. Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe. BMC Cancer 2006;6:6.
41. Wong HK. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma. Discov Med 2013;16:71-8.
42. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005;125:1045-52.
43. Hymes KB. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma. Clin Lymphoma Myeloma Leuk 2010;10:98-109.
44. Bettegowda A, Wilkinson MF. Transcription and post-transcriptional regulation of spermatogenesis. Philos Trans R Soc Lond B Biol Sci 2010;365:1637-51.
45. Chitale DA, Jungbluth AA, Marshall DS, Leitao MM, Hedvat CV, Kolb D, et al. Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. Mod Pathol 2005;18:119-26. (Pubitemid 40128104)
46. Lian Y, Sang M, Ding C, Zhou X, Fan X, Xu Y, et al. Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: a retrospective clinical study. J Cancer Res Clin Oncol 2012;138:519-27.
47. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, et al. Cancertestis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 2006;12:5442-7. (Pubitemid 44497259)
48. Theurillat JP, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B, et al. NYESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int J Cancer 2007;120:2411-7. (Pubitemid 46642128)
49. Kular RK, Yehiely F, Kotlo KU, Cilensek ZM, Bedi R, Deiss LP. GAGE, an antiapoptotic protein binds and modulates the expression of nucleophosmin/B23 and interferon regulatory factor 1. J Interferon Cytokine Res 2009;29:645-55.
50. Nylund C, Rappu P, Pakula E, Heino A, Laato L, Elo LL, et al. Mela-noma- associated cancer-testis antigen 16 (CT16) regulates the expression of apoptotic and antiapoptotic genes and promotes cell survival. PLoS One 2012;7:e45382.
51. Zeng Y, He Y, Yang F, Mooney SM, Getzenberg RH, Orban J, et al. The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein. J Biol Chem 2011;286:13985-94.
52. Cilensek ZM, Yehiely F, Kular RK, Deiss LP. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, Interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther 2002;1:380-7.
53. Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 2003;9:2778-85. (Pubitemid 36842124)
54. Zhu X, Asa SL, Ezzat S. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin Cancer Res 2008;14:1984-96. (Pubitemid 351551107)
55. van Kester MS, Borg MK, Zoutman WH, Out-Luiting JJ, Jansen PM, Dreef EJ, et al. A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. J Invest Dermatol 2012;132:2050-9.